Selenium
Selenium
What it is
Selenium is an essential trace element that functions almost exclusively through incorporation into selenoproteins — a family of around 25 proteins in which selenium is encoded as the amino acid selenocysteine. This is not incidental chemistry: selenoproteins include some of the body's most important antioxidant and metabolic enzymes, and selenium cannot be substituted by any other mineral in their synthesis.
The most clinically relevant selenoproteins include glutathione peroxidases (GPx), which protect cells from oxidative damage; thioredoxin reductases, which regulate redox signalling; and iodothyronine deiodinases, which convert inactive thyroxine (T4) into the metabolically active triiodothyronine (T3). The thyroid gland contains the highest selenium concentration of any organ in the body, a fact that reflects how central selenoprotein activity is to thyroid hormone metabolism. This biochemical foundation gives selenium a more clearly defined physiological necessity than most supplement ingredients and provides a coherent rationale for correcting deficiency or targeting specific clinical contexts where selenoprotein activity is compromised.
Selenium is obtained through food, with soil selenium content being the primary determinant of intake. Brazil nuts are uniquely concentrated — one or two nuts can provide a full day's requirement — while meat, poultry, fish, and eggs are reliable sources. Plant foods vary considerably depending on where they were grown. Dietary intake across much of Europe, including the UK, tends to be lower than in North America, where selenium-rich soils in many agricultural regions produce higher background exposure through staple foods. This geographic variability makes region-specific population selenium status difficult to characterise.
The two main supplemental forms are selenomethionine (organic, typically derived from selenium-enriched yeast) and sodium selenite (inorganic). Selenomethionine has superior bioavailability and is the form most commonly used in clinical research. The distinction between forms matters because organic and inorganic selenium are metabolised differently, stored differently, and may have different effects at equivalent doses.
What the evidence shows
Selenium's evidence profile is shaped by the distinction between two very different questions: what happens when deficiency is corrected, and what happens when selenium is added on top of adequate status. These are not the same question, and conflating them explains much of the confusion in the supplement literature.
In populations or individuals with genuinely low selenium, the evidence for harm is consistent and well-characterised: impaired thyroid hormone conversion, increased oxidative stress, compromised immune function, and — in severe endemic deficiency — Keshan disease, a potentially fatal cardiomyopathy documented historically in selenium-depleted regions of China. In these contexts, correcting selenium status has clear and well-established benefit.
In people with autoimmune thyroid disease, particularly Hashimoto's thyroiditis, there is now a substantial and consistent body of RCT evidence for biomarker effects — primarily reductions in TPOAb — without established impact on hard clinical endpoints such as prevention of progression to overt hypothyroidism. Reductions in TPOAb are consistent, but their clinical significance remains uncertain. Effect sizes are moderate, trial heterogeneity is meaningful, and whether antibody reduction translates to meaningful disease modification is not yet established. This is the strongest area of evidence for supplementation in a non-deficient population.
Evidence for cancer prevention, cardiovascular benefit, cognitive protection, and general wellness in replete populations is inconsistent or negative. The SELECT trial — a large, well-powered RCT in over 35,000 men — found no reduction in prostate cancer risk from selenium supplementation, and post-hoc analyses identified a signal of harm in selenium-replete individuals. This finding is an important anchor for the field: selenium is not a nutrient where more is better, and the dose-response relationship is U-shaped rather than linear.
Five questions
Does low status cause harm? Yes, with good evidence. Selenium deficiency impairs thyroid hormone conversion, reduces antioxidant capacity through GPx and thioredoxin reductase activity, and in severe cases causes Keshan disease and reproductive impairment. Marginal deficiency — below the threshold for overt disease but insufficient to maximise selenoprotein activity — is common in parts of Europe and associated with worse outcomes in thyroid disease and possibly fertility. This is one of the more clearly established deficiency-harm relationships among trace elements.
Does supplementation prevent disease? In Hashimoto's thyroiditis, evidence supports a reduction in antibody burden and small reductions in TSH of uncertain clinical significance, though whether this prevents progression to hypothyroidism or reduces long-term morbidity is not yet established. In the general population with adequate selenium, there is no robust evidence that supplementation prevents cancer, cardiovascular disease, or cognitive decline. The SELECT trial provides a strong signal that supplementation in already-replete individuals is unlikely to benefit and may cause harm.
Does it affect biomarkers? Yes, consistently. Selenium supplementation raises serum selenium and increases GPx activity. In Hashimoto's thyroiditis, it reduces TPOAb, and in some trials reduces TSH in those off thyroid hormone replacement. These are meaningful biomarker effects. The key interpretive caution is that GPx activity plateaus once minimal selenium requirements are met — a threshold reached at relatively modest intakes — meaning further supplementation does not produce further enzymatic benefit in replete individuals. It only raises selenium levels without corresponding functional gain, which is the basis for the upper intake concern.
Does it help clinical populations? Evidence is most developed in Hashimoto's thyroiditis, where multiple meta-analyses consistently show TPOAb reduction. The 2024 Huwiler et al. meta-analysis (35 studies, published in Thyroid) found significant effects on TSH and TPOAb in patients not on thyroid hormone replacement. In male infertility, the evidence is suggestive — selenoproteins are structurally essential for sperm formation and motility — but clinical trial evidence is inconsistent, partly reflecting the difficulty of isolating selenium from other micronutrient confounders; many trials study selenium in combination with vitamin E or other antioxidants, making selenium-specific attribution unreliable. In female fertility, data are limited and largely observational.
Does it benefit healthy individuals? For replete individuals in regions with adequate selenium intake, supplementation is unlikely to provide meaningful benefit and may cause harm at higher doses. The U-shaped dose-response relationship means that people who are already selenium-sufficient gain nothing from additional selenium and risk moving into the range associated with adverse effects. In regions of Europe with consistently lower dietary selenium, the question of adequacy is less clear-cut and population-level status should be considered before supplementing.
Individual variation
Selenium status and the benefit of supplementation vary considerably by geography, diet, and clinical context. People living in lower-selenium regions of Europe — particularly parts of the UK, Scandinavia, and Eastern Europe — are more likely to have marginal status and more likely to benefit from supplementation or dietary attention. The same dose that corrects deficiency in a European with low baseline status may push someone with naturally higher intake from North American agricultural regions into a harmful range.
People with Hashimoto's thyroiditis have the most developed evidence base for supplementation regardless of baseline status, and selenium is increasingly considered as an adjunct to standard management in this condition. Those with other autoimmune thyroid conditions, including Graves' disease, have some supporting evidence but a less well-characterised benefit profile.
Women of reproductive age with thyroid autoimmunity represent a population where selenium status is particularly relevant given the intersection of thyroid function and reproductive outcomes. The thyroid-sex hormone axis means that poorly managed Hashimoto's disease has downstream consequences for fertility, and selenium's role in thyroid antibody reduction is therefore indirectly relevant to this group.
Vegetarians and vegans eating from low-selenium soils may be at meaningful risk of insufficiency, since plant-based selenium sources are highly variable. Brazil nuts are an efficient dietary correction but are themselves inconsistent in selenium content. Testing is useful in this group before long-term supplementation.
Men with subfertility represent another population of interest, given the structural role of selenoproteins in sperm architecture, though clinical trial evidence in this group remains inconsistent and does not yet support a routine recommendation.
Testing and status assessment
Serum or plasma selenium reflects recent dietary intake and short-term status over preceding weeks. Whole blood selenium is a better indicator of longer-term status, reflecting intake over several months. Selenoprotein P (SePP) is considered the most reliable functional marker of selenium status and is increasingly used in research, though it is not routinely available in clinical practice.
Glutathione peroxidase (GPx) activity can also be measured and was historically used as a functional marker, but its utility is limited by a plateau effect: GPx activity reaches its maximum at relatively modest selenium intakes and does not continue to rise with further supplementation. This makes it useful for detecting deficiency but not for titrating optimal intake.
Standard serum selenium testing is available through most clinical laboratories. For most people, this provides a sufficient basis for a supplementation decision, particularly if there is a clinical indication such as Hashimoto's thyroiditis or a diet that restricts reliable selenium sources.
Safety
The tolerable upper intake level (UL) for selenium is 400 micrograms per day for adults, set on the basis of selenosis — a toxicity syndrome characterised by hair and nail loss, a garlic-like breath odour, gastrointestinal disturbance, fatigue, and in severe cases neurological symptoms. Selenosis is most commonly associated with very high-dose supplementation or consumption from unusually selenium-rich water or soil.
The U-shaped dose-response relationship is the single most important safety consideration for selenium. The margin between adequate intake and potentially harmful intake is smaller than for many micronutrients. Optimal selenium status appears to lie within a relatively narrow range: functional benefit from selenoproteins is achieved at intakes around 70 to 100 micrograms per day, and potential risk begins to emerge above approximately 200 micrograms per day in individuals who are already replete. This makes baseline status assessment important before supplementing, as the same dose may be corrective in one individual and excessive in another. In practice, 100 micrograms per day is typically sufficient to correct marginal deficiency; doses of 200 micrograms and above may not provide additional benefit in replete individuals and may carry risk. The SELECT trial's post-hoc findings identifying a signal of harm in selenium-replete men who supplemented at 200 micrograms per day is a clinically important signal, even though the trial was not designed to detect this outcome.
Drug interactions are limited but relevant in specific contexts. Selenium may interact with chemotherapy agents, and people undergoing cancer treatment should not supplement without medical guidance. Anticoagulant interactions are theoretically possible through selenium's effects on platelet function, though clinical significance remains uncertain.
Pregnancy requires particular attention. Selenium is essential for foetal development and placental selenoprotein expression, and both deficiency and excess during pregnancy carry risk. Supplementation in pregnant women with confirmed deficiency or Hashimoto's thyroiditis should be managed with monitoring rather than self-supplemented at arbitrary doses. Standard prenatal multivitamins typically contain 50 to 70 micrograms of selenium, which is generally appropriate for replete women.
What can reasonably be concluded
Selenium is one of the few supplement ingredients where the biological rationale is grounded in a clearly established essential function rather than in speculative extrapolation from antioxidant chemistry. The selenoprotein system is real, the deficiency consequences are documented, and the thyroid-selenium relationship is one of the most mechanistically coherent in nutritional science.
The evidence for supplementation is strongest where status is genuinely low or where there is a clinical condition — particularly Hashimoto's thyroiditis — where selenoprotein activity appears to modulate disease-associated biomarkers. The evidence for supplementation in healthy, replete individuals is weak and carries meaningful risk of harm at higher doses. The SELECT trial outcome should be read seriously: selenium is not a nutrient that confers benefit in proportion to dose, and the instinct to supplement more when unsure of status is likely to be counterproductive for a meaningful proportion of users.
For people in lower-selenium regions, with confirmed or probable deficiency, or with Hashimoto's thyroiditis, the case for supplementation is reasonable and proportionate. For healthy individuals with adequate dietary selenium, routine supplementation is not supported by the evidence and is not without risk. Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.